Enzo Biochem, Inc. (ENZB)
OTCMKTS
· Delayed Price · Currency is USD
0.4500
+0.0550 (13.92%)
At close: Apr 23, 2025
Enzo Biochem Revenue
Enzo Biochem had revenue of $7.33M in the quarter ending January 31, 2025, a decrease of -14.25%. This brings the company's revenue in the last twelve months to $29.09M, down -11.31% year-over-year. In the fiscal year ending July 31, 2024, Enzo Biochem had annual revenue of $31.91M with 2.72% growth.
Revenue (ttm)
29.09M
Revenue Growth
-11.31%
P/S Ratio
0.81
Revenue / Employee
222.09K
Employees
136
Market Cap
23.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jul 31, 2024 | 31.91M | 846.00K | 2.72% |
Jul 31, 2023 | 31.06M | -1.58M | -4.85% |
Jul 31, 2022 | 32.64M | -85.09M | -72.27% |
Jul 31, 2021 | 117.73M | 41.71M | 54.87% |
Jul 31, 2020 | 76.02M | -5.15M | -6.34% |
Jul 31, 2019 | Pro | Pro | Pro |
Jul 31, 2018 | Pro | Pro | Pro |
Jul 31, 2017 | Pro | Pro | Pro |
Jul 31, 2016 | Pro | Pro | Pro |
Jul 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Federal National Mortgage Association | 31.05B |
Federal Home Loan Mortgage | 23.44B |
Music Licensing | 128.87M |
Alpine Auto Brokers | 129.78K |
Central Bancompany | 883.13M |
Jingbo Technology | 1.96M |
First National of Nebraska | 1.89B |
Mechanics Bank | 381.61M |
Enzo Biochem News
- 1 day ago - Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction - GlobeNewsWire
- 26 days ago - Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - GlobeNewsWire
- 5 weeks ago - Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results - GlobeNewsWire
- 3 months ago - Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules - GlobeNewsWire
- 4 months ago - Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update - GlobeNewsWire
- 6 months ago - Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend - GlobeNewsWire
- 9 months ago - Enzo Biochem to pay $4.5 mln for failing to safeguard patient data - Reuters
- 10 months ago - Enzo Biochem: Is This Time Finally Different? - Seeking Alpha